Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

52.17
+0.50000.97%
Post-market: 52.170.00000.00%16:58 EDT
Volume:1.84M
Turnover:95.50M
Market Cap:4.51B
PE:-11.55
High:53.08
Open:52.36
Low:51.15
Close:51.67
Loading ...

2 Beaten-Down Stocks With Massive Upside Potential

Motley Fool
·
03 Jul

2 Growth Stocks to Buy Hand Over Fist in July

Motley Fool
·
02 Jul

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and Pharvaris (PHVS)

TIPRANKS
·
30 Jun

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

Motley Fool
·
28 Jun

Crispr Therapeutics Price Target Maintained With a $65.00/Share by HC Wainwright & Co.

Dow Jones
·
27 Jun

Crispr Therapeutics AG (CRSP) Gets a Hold from Barclays

TIPRANKS
·
27 Jun

Crispr posts strong CTX310 data, says Chardan

TIPRANKS
·
26 Jun

Strategic Alignment and Positive Clinical Data Reinforce Buy Rating for Crispr Therapeutics AG

TIPRANKS
·
26 Jun

CRISPR Therapeutics Advances Phase 1 Trials for Cardiovascular Disease Programs

MT Newswires Live
·
26 Jun

Crispr Therapeutics Reports Positive Additional Phase 1 Data For Ctx310™ Targeting Angptl3 And Provides Update On In Vivo Cardiovascular Pipeline

Reuters
·
26 Jun

The Best Stocks to Invest $1,000 in Right Now

Motley Fool
·
24 Jun

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts

Motley Fool
·
22 Jun

Crispr Therapeutics AG (CRSP) Gets a Hold from Bernstein

TIPRANKS
·
20 Jun

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

Motley Fool
·
17 Jun

CRISPR Therapeutics AG Held Annual General Meeting of Shareholders

Reuters
·
10 Jun

Crispr Therapeutics AG: Stock Soars Amid Bullish Trends

TIPRANKS
·
07 Jun

CRISPR Therapeutics AG Files Initial Beneficial Ownership Statement for Director Morrison Briggs

Reuters
·
07 Jun

Crispr Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
06 Jun

Bernstein Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
06 Jun

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Zacks
·
04 Jun